Recent clinical findings on the role of kinase inhibitors in COVID-19 management.


Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
01 Oct 2022
Historique:
received: 18 05 2022
revised: 07 07 2022
accepted: 11 07 2022
pubmed: 17 7 2022
medline: 24 8 2022
entrez: 16 7 2022
Statut: ppublish

Résumé

The highly pathogenic, novel coronavirus disease (COVID-19) outbreak has emerged as a once-in-a-century pandemic with poor consequences, urgently calling for new therapeutics, cures, and supportive interventions. It has already affected over 250 million people worldwide; thereby, there is a need for novel therapies to alleviate the related complications. There is a paradigm shift in developing drugs and clinical practices to combat COVID-19. Several clinical trials have been performed or are testing diverse pharmacological interventions to alleviate viral load and complications such as cytokine release storm (CRS). Kinase-inhibitors have appeared as potential antiviral agents for COVID-19 patients due to their efficacy against CRS. Combination of kinase inhibitors with other therapies can achieve more efficacy against COVID-19. Based on the pre-clinical trials, kinase inhibitors such as Janus kinase-signal transducer and activator of transcription (JAK/STAT) inhibitors, Brutton's tyrosin kinase (BTK) inhibitors, p38 mitogen-activated protein kinases (p38 MAPK) inhibitors, Glycogen synthase kinase 3 (GSK-3) inhibitors can be a promising strategy against COVID-19. Kinase inhibitors possess crucial pharmacological properties for a successful re-purposing in terms of dual anti-inflammatory and anti-viral effects. This review will address the current clinical evidence and the newest discovery regarding the application of kinase inhibitors in COVID-19. An outlook on ongoing clinical trials (clinicaltrials.gov) and unpublished data is also presented here. Besides, Kinase inhibitors' function on COVID-19-mediated CRS is discussed.

Identifiants

pubmed: 35841979
pii: S0024-3205(22)00509-4
doi: 10.1016/j.lfs.2022.120809
pmc: PMC9278000
pii:
doi:

Substances chimiques

Antiviral Agents 0
p38 Mitogen-Activated Protein Kinases EC 2.7.11.24
Glycogen Synthase Kinase 3 EC 2.7.11.26

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

120809

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Références

Mol Cancer Res. 2021 Apr;19(4):549-554
pubmed: 33328281
Front Biosci (Landmark Ed). 2020 Mar 1;25(7):1361-1385
pubmed: 32114437
Biochem J. 2010 Aug 1;429(3):403-17
pubmed: 20626350
Clin Infect Dis. 2021 Apr 8;72(7):1247-1250
pubmed: 32597466
Immunity. 2016 Feb 16;44(2):274-86
pubmed: 26885856
J Exp Med. 2021 Nov 1;218(11):
pubmed: 34554188
Pharmacol Rev. 2016 Jul;68(3):788-815
pubmed: 27363440
PLoS One. 2016 Feb 22;11(2):e0149486
pubmed: 26901653
Mol Med Rep. 2020 Aug;22(2):1656-1662
pubmed: 32626961
PLoS One. 2017 Jul 3;12(7):e0180088
pubmed: 28672038
Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031
pubmed: 32700604
Cytokine Growth Factor Rev. 2020 Aug;54:51-62
pubmed: 32636055
Cytokine Growth Factor Rev. 2021 Apr;58:92-101
pubmed: 32948440
Nat Rev Immunol. 2010 Mar;10(3):170-81
pubmed: 20154735
J Biol Chem. 2009 Feb 20;284(8):5229-39
pubmed: 19106108
Int J Mol Med. 2018 Jan;41(1):409-420
pubmed: 29138810
Immunotherapy. 2021 Mar;13(4):289-295
pubmed: 33397150
J Clin Invest. 2020 Dec 1;130(12):6409-6416
pubmed: 32809969
Gastroenterol Hepatol. 2022 May;45(5):383-389
pubmed: 34171421
Virol J. 2022 May 26;19(1):92
pubmed: 35619180
Eur J Med Chem. 2019 Feb 1;163:413-427
pubmed: 30530193
Daru. 2020 Jun;28(1):159-169
pubmed: 31942696
Leukemia. 2021 Apr;35(4):1121-1133
pubmed: 32814839
Cell. 2021 Jan 21;184(2):460-475.e21
pubmed: 33278358
Hum Mol Genet. 2012 Oct 1;21(19):4325-33
pubmed: 22773734
Int J Mass Spectrom. 2007 Dec 1;268(2):296-303
pubmed: 32288628
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Lancet. 2018 Feb 17;391(10121):659-667
pubmed: 29241979
Mayo Clin Proc Innov Qual Outcomes. 2021 Jun;5(3):605-613
pubmed: 33817559
J Med Chem. 2010 Mar 25;53(6):2345-53
pubmed: 19950901
Reumatol Clin (Engl Ed). 2020 Nov 28;:
pubmed: 33358361
Pharmacol Res. 2020 Aug;158:104850
pubmed: 32360580
J Allergy Clin Immunol. 2017 Oct;140(4):1054-1067.e10
pubmed: 28216434
Int J Biol Sci. 2022 Jan 1;18(2):459-472
pubmed: 35002503
Drugs. 2019 Feb;79(3):331-339
pubmed: 30721452
Biochem Biophys Res Commun. 2018 May 5;499(2):260-266
pubmed: 29567473
Biochim Biophys Acta. 2016 Nov;1860(11 Pt A):2335-2344
pubmed: 27369736
Leukemia. 2021 Oct;35(10):2917-2923
pubmed: 34385593
Pharm Res. 2020 Aug 10;37(9):167
pubmed: 32778962
Metabol Open. 2021 Sep;11:100116
pubmed: 34345815
Nat Rev Mol Cell Biol. 2018 May;19(5):313-326
pubmed: 29410531
Cancers (Basel). 2018 May 03;10(5):
pubmed: 29751559
Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1199-203
pubmed: 15130920
Target Oncol. 2020 Oct;15(5):681-689
pubmed: 32940858
Lancet. 2020 Feb 15;395(10223):e30-e31
pubmed: 32032529
J Allergy Clin Immunol. 2020 Jul;146(1):137-146.e3
pubmed: 32470486
Pharmacotherapy. 2020 Aug;40(8):843-856
pubmed: 32542785
Int J Antimicrob Agents. 2020 May;55(5):105967
pubmed: 32259575
Cell Host Microbe. 2014 Oct 8;16(4):462-72
pubmed: 25299332
Science. 2020 May 1;368(6490):473-474
pubmed: 32303591
Int J Chron Obstruct Pulmon Dis. 2016 Apr 29;11:909-17
pubmed: 27199554
J Infect. 2020 Oct;81(4):647-679
pubmed: 32592703
Comput Struct Biotechnol J. 2021;19:976-988
pubmed: 33558827
Sci Rep. 2014 Nov 13;4:7027
pubmed: 25391767
Expert Opin Biol Ther. 2021 May;21(5):675-686
pubmed: 33835886
Hum Exp Toxicol. 2021 Aug;40(8):1263-1273
pubmed: 33559503
Trends Mol Med. 2002 Mar;8(3):126-32
pubmed: 11879773
Recent Results Cancer Res. 2018;212:119-132
pubmed: 30069628
J Infect. 2021 Apr;82(4):58-66
pubmed: 33639176
J Med Chem. 2022 Jan 27;65(2):893-921
pubmed: 33539089
Pharmaceuticals (Basel). 2021 Jul 28;14(8):
pubmed: 34451835
J Med Chem. 2022 Jan 27;65(2):955-982
pubmed: 34081439
J Transl Med. 2020 Sep 15;18(1):353
pubmed: 32933536
Annu Rev Med. 2022 Jan 27;73:65-80
pubmed: 34437814
N Engl J Med. 2021 Jul 29;385(5):406-415
pubmed: 34133856
Front Immunol. 2017 Dec 11;8:1653
pubmed: 29312284
Clin Sci (Lond). 2020 Aug 28;134(16):2137-2160
pubmed: 32820801
Adv Biol Regul. 2017 Aug;65:5-15
pubmed: 28712664
Pulm Pharmacol Ther. 2021 Aug;69:102039
pubmed: 34023513
Eur J Pharmacol. 2021 Jun 15;901:174082
pubmed: 33823185
Cell. 2020 Aug 6;182(3):685-712.e19
pubmed: 32645325
Br J Haematol. 2020 Aug;190(4):e189-e191
pubmed: 32584418
N Engl J Med. 2021 Mar 4;384(9):795-807
pubmed: 33306283
Br J Pharmacol. 2013 Jun;169(3):477-92
pubmed: 23488800
Biomed Pharmacother. 2022 Mar;147:112614
pubmed: 34995938
Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5
pubmed: 14585926
Front Immunol. 2020 Jun 26;11:1638
pubmed: 32695123
Front Pharmacol. 2020 Jun 05;11:857
pubmed: 32581810
Clin Immunol. 2020 Sep;218:108517
pubmed: 32585295
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Mol Med Rep. 2017 Dec;16(6):9652-9658
pubmed: 29039541
Haematologica. 2021 Aug 01;106(8):2265-2268
pubmed: 33691383
Inflammopharmacology. 2021 Feb;29(1):91-100
pubmed: 33159646
Mol Cancer. 2019 Feb 11;18(1):24
pubmed: 30744655
Postgrad Med. 2021 Jun;133(5):489-507
pubmed: 33245005
Biochem J. 2008 Feb 1;409(3):635-49
pubmed: 18177271
J Mol Cell Cardiol. 2020 Jul;144:63-65
pubmed: 32422320
Front Immunol. 2017 Nov 08;8:1454
pubmed: 29167667
Rheumatology (Oxford). 2021 Jan 5;60(1):399-407
pubmed: 33020836
Virology. 2007 Sep 1;365(2):324-35
pubmed: 17490702
PLoS One. 2011 May 06;6(5):e18669
pubmed: 21573100
Indian J Pharmacol. 2021 May-Jun;53(3):246-247
pubmed: 34169913
Circulation. 1999 Apr 6;99(13):1685-91
pubmed: 10190877
Nature. 2020 Jun;582(7811):289-293
pubmed: 32272481
Nat Commun. 2013;4:1833
pubmed: 23673618
Eur J Pharmacol. 2019 Nov 5;862:172623
pubmed: 31445014
Immun Ageing. 2020 Nov 14;17(1):34
pubmed: 33292350
Lancet Infect Dis. 2020 Sep;20(9):1012-1013
pubmed: 32251638
Nature. 2022 Mar;603(7902):715-720
pubmed: 35104836
Int Rev Immunol. 2022;41(2):217-230
pubmed: 33616462
Expert Rev Clin Immunol. 2019 Jul;15(7):693-700
pubmed: 30987474
J Biol Chem. 2011 Oct 14;286(41):35466-35476
pubmed: 21865167
Trends Pharmacol Sci. 2015 Jul;36(7):422-39
pubmed: 25975227
Cytokine. 2020 Sep;133:155151
pubmed: 32544563
Cells. 2021 Jan 28;10(2):
pubmed: 33525562
Clin Cancer Res. 2020 Jul 15;26(14):3514-3516
pubmed: 32345646
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503877
J Virol. 2006 Jan;80(2):785-93
pubmed: 16378980
Bioimpacts. 2023;13(1):51-61
pubmed: 36816998
Proc Natl Acad Sci U S A. 2021 Oct 19;118(42):
pubmed: 34593624
J Clin Invest. 2012 Dec;122(12):4555-68
pubmed: 23187130
Theranostics. 2016 Feb 17;6(4):571-93
pubmed: 26941849

Auteurs

Zahra Malekinejad (Z)

Faculty of Veterinary Medicine, Tabriz Branch, Islamic Azad University, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Amir Baghbanzadeh (A)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Ailar Nakhlband (A)

Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Behzad Baradaran (B)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Sevda Jafari (S)

Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Yasin Bagheri (Y)

Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Faezeh Raei (F)

Departement of Chemical and Petroleum Engineering, Sharif University of Technology, Tehran, Iran.

Soheila Montazersaheb (S)

Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: montazersahebs@tbzmed.ac.ir.

Raheleh Farahzadi (R)

Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: farahzadir@tbzmed.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH